Last reviewed · How we verify
PRE-TRANSPLANT (PRE=before)
Pre-transplant conditioning refers to preparatory treatment regimens administered before organ transplantation to suppress the recipient's immune system and prepare the body for graft acceptance.
Pre-transplant conditioning refers to preparatory treatment regimens administered before organ transplantation to suppress the recipient's immune system and prepare the body for graft acceptance. Used for Preparation for organ transplantation (kidney, heart, liver, lung, or bone marrow).
At a glance
| Generic name | PRE-TRANSPLANT (PRE=before) |
|---|---|
| Sponsor | Josep M Grinyo |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Pre-transplant protocols typically involve immunosuppressive chemotherapy, radiation, or antibody-based therapies designed to deplete or inactivate the recipient's T cells and other immune effector cells. This conditioning creates an immunologic environment permissive for donor organ engraftment while minimizing rejection risk. The specific regimen varies by transplant type and donor-recipient matching.
Approved indications
- Preparation for solid organ transplantation (kidney, heart, liver, lung)
- Preparation for hematopoietic stem cell transplantation
Common side effects
- Myelosuppression
- Infection
- Mucositis
- Nausea and vomiting
- Graft-versus-host disease (GVHD)
Key clinical trials
- Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
- LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma (PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
- Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
- Using Breathing Techniques to Ease Anxiety in ICU Patients Awaiting Heart Transplants (NA)
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRE-TRANSPLANT (PRE=before) CI brief — competitive landscape report
- PRE-TRANSPLANT (PRE=before) updates RSS · CI watch RSS
- Josep M Grinyo portfolio CI